Bluebird Bio Has Agreed To Sell A Rare Pediatric Disease Priority Review Voucher, If Received, Related To Potential Approval Of Lovotibeglogene Autotemcel (Lovo-cel) For Sickle Cell Disease, For $103M
Portfolio Pulse from Benzinga Newsdesk
Bluebird Bio has agreed to sell a potential Rare Pediatric Disease Priority Review Voucher (PRV) for $103 million, contingent on FDA approval of the biologics license application for Lovotibeglogene Autotemcel (Lovo-cel) for Sickle Cell Disease.
October 30, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The sale of the PRV could provide Bluebird Bio with a significant cash influx of $103 million, contingent on FDA approval of Lovo-cel.
The sale of the PRV, if approved, would provide Bluebird Bio with a significant cash influx. This could potentially improve the company's financial position and could be seen as a positive by investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100